Can dapagliflozin be prescribed for a patient with an estimated glomerular filtration rate (eGFR) of 33 mL/min/1.73 m²?

Yes, dapagliflozin can be given to a patient with an eGFR of 33 mL/min/1.73 m²

For patients with an eGFR of 33 mL/min/1.73 m², dapagliflozin 10 mg daily is appropriate and recommended, as this falls within the approved range for initiation (eGFR ≥25 mL/min/1.73 m²) for cardiovascular and kidney protection indications. 1

Indication-Specific Guidance

For Kidney Protection, Heart Failure, or Cardiovascular Risk Reduction

• Initiate dapagliflozin 10 mg daily if eGFR ≥25 mL/min/1.73 m² 1
• With an eGFR of 33, this patient is well above the initiation threshold
• The 2022 ADA/KDIGO consensus guidelines strongly support SGLT2 inhibitor use for patients with eGFR ≥20 mL/min/1.73 m² 2
• Continue treatment even if eGFR subsequently falls below 25 mL/min/1.73 m² for ongoing kidney and cardiovascular benefit 2

For Glycemic Control in Type 2 Diabetes

• Do NOT initiate dapagliflozin for glycemic control purposes when eGFR <45 mL/min/1.73 m² 1
• The drug is ineffective for glucose lowering at this level of kidney function due to its mechanism of action
• However, if already on dapagliflozin when eGFR was higher, continuation is appropriate for cardiorenal benefits

Clinical Context and Evidence

The DAPA-CKD trial provides robust evidence supporting dapagliflozin use at this eGFR level. This landmark study enrolled patients with eGFR 25-75 mL/min/1.73 m² and demonstrated:

• 39% reduction in the composite of sustained eGFR decline ≥50%, end-stage kidney disease, or renal/cardiovascular death 3
• 31% reduction in all-cause mortality 3
• Slowed eGFR decline by approximately 1 mL/min/1.73 m² per year 4
• Benefits were consistent regardless of diabetes status 3

Important Practical Considerations

Expected Initial eGFR Dip

• Anticipate an acute, reversible eGFR decline of 2-3 mL/min/1.73 m² within the first 2 weeks 5
• This hemodynamic effect does NOT predict worse long-term outcomes 5
• Do not discontinue therapy based on this expected initial decline
• Patients experiencing this acute dip actually had better long-term kidney function preservation 5

Monitoring Requirements

• Assess volume status before initiation; correct any volume depletion first 1
• Monitor for hypovolemia, especially in elderly patients or those on diuretics 2
• Consider proactive diuretic dose reduction in high-risk patients 2
• Institute a "sick day protocol" - hold dapagliflozin during acute illness 2

Safety Profile at This eGFR Level

Recent pharmacokinetic data confirms safety in stage 4 CKD (eGFR 15-30):

• No clinically significant drug accumulation with repeated dosing 6
• Dapagliflozin is rapidly absorbed and metabolized 6
• Reduction in albuminuria observed even at low eGFR 6

Common Pitfalls to Avoid

1. Don't confuse glycemic control indication with cardiorenal protection indication - The eGFR thresholds differ significantly (45 vs 25 mL/min/1.73 m²)

2. Don't discontinue due to initial eGFR decline - The acute 2-3 mL/min/1.73 m² drop in the first 2 weeks is expected and reversible 5

3. Don't withhold in patients without diabetes - Benefits for kidney and cardiovascular protection are independent of diabetes status 3

4. Don't forget to counsel on genital hygiene - Genital mycotic infections occur in ~6% of patients 2

5. Don't use in patients requiring immunosuppression for kidney disease - Dapagliflozin is not expected to be effective in these populations 1

Dosing Algorithm

eGFR 33 mL/min/1.73 m²:

• ✓ Start dapagliflozin 10 mg daily for CKD progression risk reduction, heart failure, or cardiovascular protection
• ✗ Do not start for glycemic control alone
• ✓ Continue if already on therapy when eGFR was higher
• ✓ Maintain even if eGFR subsequently drops to 25-33 range
• ✓ Can continue if eGFR falls below 25 after initiation 1

The evidence strongly supports dapagliflozin use at an eGFR of 33 mL/min/1.73 m² for cardiorenal protection, with proven mortality and kidney failure risk reduction 3.